Windows of opportunity for Ebola virus infection treatment and vaccination

Scientific Reports

Volumn 7, Issue 1, 2017, Pages

  Nguyen, Van Kinh ^a,b   Hernandez Vargas, Esteban A ^a,b  

^a FRANKFURT INSTITUTE FOR ADVANCED STUDIES   (Germany)

^b HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EBOLA VACCINE;

ANIMAL; DISEASE MODEL; EBOLA HEMORRHAGIC FEVER; IMMUNOLOGY; PASSIVE IMMUNIZATION; PATHOLOGY; PRIMATE; PROCEDURES; THEORETICAL MODEL; TIME FACTOR;

ANIMALS; DISEASE MODELS, ANIMAL; EBOLA VACCINES; HEMORRHAGIC FEVER, EBOLA; IMMUNIZATION, PASSIVE; MODELS, THEORETICAL; PRIMATES; TIME FACTORS;

EID: 85027893883     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-017-08884-0     Document Type: Article

References (47)

1. Van Kerkhove, M. D., Bento, A. I., Mills, H. L., Ferguson, N. M., & Donnelly, C. A. A review of epidemiological parameters from Ebola outbreaks to inform early public health decision-making. Sci. Data 2, 150019, doi: 10.1038/sdata.2015.19 (2015
2. World Health Organization. Ebola Situation Reports. http://apps.who.int/ebola/ebola-situation-reports (2017
3. Prescott, J. B., et al. Immunobiology of Ebola and Lassa virus infections. Nat. Rev. Immunol. 17, 195-207, doi: 10.1038/nri.2016.138 (2017
4. Madelain, V., et al. Ebola Virus Infection: Review of the Pharmacokinetic and Pharmacodynamic Properties of Drugs Considered for Testing in Human Efficacy Trials. Clin. Pharmacokinet. 55, 907-923, doi: 10.1007/s40262-015-0364-1 (2016
5. Richardson, T., Johnston, A. M., & Draper, H. A Systematic Review of Ebola Treatment Trials to Assess the Extent to Which They Adhere to Ethical Guidelines. PLoS One 12, e0168975, doi: 10.1371/journal.pone.0168975 (2017
6. Cardile, A. P., Warren, T. K., Martins, K. A., Reisler, R. B., & Bavari, S. Will There Be a Cure for Ebola? Annu. Rev. Pharmacol. Toxicol. 57, 329-348 (2016
7. Pavot, V. Ebola virus vaccines: Where do we stand? Clin. Immunol. 173, 44-49, doi: 10.1016/j.clim.2016.10.016 (2016
8. Martins, K. A., Jahrling, P. B., Bavari, S., & Kuhn, J. H. Ebola virus disease candidate vaccines under evaluation in clinical trials. Expert. review 15, 1101-1112, doi: 10.1080/14760584.2016.1187566 (2016
9. Heppner, D. G., et al. Safety and immunogenicity of the rVSV?G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study. The Lancet Infect. Dis. 0, doi: 10.1016/S1473-3099(17)30313-4 (2017
10. Qiu, X., et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nat. 1-15, doi: 10.1038/nature13777 (2014
11. Marzi, A., et al. VSV-EBOV rapidly protects macaques against infection with the 2014/15 Ebola virus outbreak strain. Sci. 349, 739-742, doi: 10.1126/science.aab3920 (2015
12. Henao-Restrepo, A. M., et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit). The Lancet 389, 505-518, doi: 10.1016/S0140-6736(16)32621-6 (2017
13. Nowak, M. A., & May, R. M. Virus Dynamics: Mathematical Principles of Immunology and Virology: Mathematical Principles of Immunology and Virology (Oxford University Press, UK, 2000
14. Smith, A. M., & Perelson, A. S. Influenza A virus infection kinetics: quantitative data and models. Wiley Interdiscip. Rev. Syst. Biol. Medicine 3, 429-445, doi: 10.1002/wsbm.129 (2010
15. Beauchemin, C. A., & Handel, A. A review of mathematical models of influenza A infections within a host or cell culture: lessons learned and challenges ahead. BMC Public Heal. 11, S7, doi: 10.1186/1471-2458-11-S1-S7 (2011
16. Duvigneau, S., et al. Hierarchical effects of pro-inflammatory cytokines on the post-influenza susceptibility to pneumococcal coinfection. Sci. Reports 6, 643, doi: 10.1038/srep37045 (2016
17. Hernandez-Vargas, E. A., et al. Effects of Aging on Influenza Virus Infection Dynamics. J. Virol. 88, 4123-4131, doi: 10.1128/JVI.03644-13 (2014
18. Boianelli, A., et al. Modeling Influenza Virus Infection: A Roadmap for Influenza Research. Viruses 7, 5274-5304, doi: 10.3390/v7102875 (2015
19. Saber, C. N., Larsen, C. G., Dalianis, T., & von Buchwald, C. Immune cells and prognosis in HPV-associated oropharyngeal squamous cell carcinomas: Review of the literature. Oral. Oncol. 58, 8-13, doi: 10.1016/j.oraloncology.2016.04.004 (2016
20. Hernandez-Vargas, E. A., & Colaneri, P. Switching strategies to mitigate HIV mutation. on Control. Syst. Technol., doi: 10.1109/TCST.2013.2280920 (2014
21. Conway, J. M., & Perelson, A. S. Post-treatment control of HIV infection. Proc. Natl. Acad. Sci. United States Am. 112, 5467-5472, doi: 10.1073/pnas.1419162112 (2015
22. Hadjiandreou, M. M., Conejeros, R., & Wilson, D. I. Long-term HIV dynamics subject to continuous therapy and structured treatment interruptions. Chem. Eng. Sci. 64, 1600-1617, doi: 10.1016/j.ces.2008.12.010 (2009
23. Ferreira, J., Hernandez-Vargas, E. A., & Middleton, R. H. Computer simulation of structured treatment interruption for HIV infection. Comput. methods programs biomedicine 104, 50-61, doi: 10.1016/j.cmpb.2011.07.011 (2011
24. Hernandez-Vargas, E. A., Colaneri, P., & Middleton, R. H. Optimal therapy scheduling for a simplified HIV infection model. Autom. 49, 2874-2880, doi: 10.1016/j.automatica.2013.06.001 (2013
25. Nguyen, V. K., Binder, S. C., Boianelli, A., Meyer-Hermann, M., & Hernandez-Vargas, E. A. Ebola virus infection modeling and identifiability problems. Front. Microbiol. 6, 7590, doi: 10.3389/fmicb.2015.00257 (2015
26. Khurana, S., et al. Human antibody repertoire after VSV-Ebola vaccination identifies novel targets and virus-neutralizing IgM antibodies. Nat. Med. 22, 1439-1447, doi: 10.1038/nm.4201 (2016
27. Dahlke, C., et al. Dose-dependent T-cell Dynamics and Cytokine Cascade Following rVSV-ZEBOV Immunization. EBioMedicine 19, 107-118, doi: 10.1016/j.ebiom.2017.03.045 (2017
28. Marzi, A., et al. Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates. Proc. Natl. Acad. Sci. 110, 1893-1898, doi: 10.1073/pnas.1209591110 (2013
29. Jones, S. M., et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat. Med. 11, 786-790, doi: 10.1038/nm1258 (2005
30. Sullivan, N. J., Martin, J. E., Graham, B. S., & Nabel, G. J. Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule. Nat. Rev. Microbiol. 7, 393-400, doi: 10.1038/nrmicro2129 (2009
31. Marzi, A., et al. Efficacy of Vesicular Stomatitis Virus-Ebola Virus Postexposure Treatment in Rhesus Macaques Infected With Ebola Virus Makona. J. Infect. Dis. 214, S360-S366, doi: 10.1093/infdis/jiw218 (2016
32. Sullivan, N. J., Yang, Z.-Y., & Nabel, G. J. Ebola Virus Pathogenesis: Implications for Vaccines and Therapies. J. Virol. 77, 9733-9737, doi: 10.1128/JVI.77.18.9733-9737.2003 (2003
33. Liu, W. M., van der Zeijst, B. A. M., Boog, C. J. P., & Soethout, E. C. Aging and impaired immunity to influenza viruses: Implications for vaccine development. Hum. Vaccines 7, 94-98, doi: 10.4161/hv.7.0.14568 (2014
34. Abbas, A. K. B Cell Activation and Antibody Production. In Cellular and Molecular Immunology, 1-26 (Elsevier Health Sciences, 2011
35. De Silva, N. S., & Klein, U. Dynamics of B cells in germinal centres. Nat. Rev. Immunol. 15, 137-148, doi: 10.1038/nri3804 (2015
36. Pound, J. Immunochemical Protocols. Methods in molecular biology (Humana Press, 1998
37. Hattori, T., et al. Antigen clasping by two antigen-binding sites of an exceptionally specific antibody for histone methylation. Proc. Natl. Acad. Sci. United States Am. 113, 2092-2097, doi: 10.1073/pnas.1522691113 (2016
38. Oprea, M., & Perelson, A. S. Exploring the mechanisms of primary antibody responses to T cell-dependent antigens. J. Theor. Biol. 181, 215-235, doi: 10.1006/jtbi.1996.0127 (1996
39. Antia, R., Bergstrom, C. T., Pilyugin, S. S., Kaech, S. M., & Ahmed, R. Models of CD8+ Responses: 1. What is the Antigenindependent Proliferation Program. J. Theor. Biol. 221, 585-598, doi: 10.1006/jtbi.2003.3208 (2003
40. Moreira, J. S., & Faro, J. Modelling Two Possible Mechanisms for the Regulation of the Germinal Center Dynamics. The J. Immunol. 177, 3705-3710, doi: 10.4049/jimmunol.177.6.3705 (2006
41. Haas, A., Zimmermann, K., & Oxenius, A. Antigen-dependent and -independent mechanisms of T and B cell hyperactivation during chronic HIV-1 infection. J. Virol. 85, 12102-12113, doi: 10.1128/JVI.05607-11 (2011
42. Keizer, R. J., Huitema, A. D. R., Schellens, J. H. M., & Beijnen, J. H. Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies. Clin. Pharmacokinet. 49, 493-507, doi: 10.2165/11531280-000000000-00000 (2010
43. Haigwood, N. L., & Walker, C. M. Chimpanzees in Biomedical and Behavioral Research. Assessing the Necessity (The National Academies Press, Washington, DC, 2011
44. Messaoudi, I., Estep, R., Robinson, B., & Wong, S. W. Nonhuman Primate Models of Human Immunology. Antioxidants, & Redox Signal. 14, 261-273, doi: 10.1089/ars.2010.3241 (2011
45. Chan, K. H., et al. Analytical Sensitivity of Seven Point-of-Care Influenza Virus Detection Tests and Two Molecular Tests for Detection of Avian Origin H7N9 and Swine Origin H3N2 Variant Influenza A Viruses. J. Clin. Microbiol. 51, 3160-3161, doi: 10.1128/JCM.01222-13 (2013
46. Storn, R., & Price, K. Differential Evolution -A Simple and Efficient Heuristic for global Optimization over Continuous Spaces. J. Glob. Optim. 11, 341-359, doi: 10.1023/A: 1008202821328 (1997
47. R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria (2015